Bon Natural Life Limited announced that it has successfully developed new nutraceutical compounds – Glucoraphanin ("GF") and Sulforaphane ("SFN"), both of which are compounds extracted from cruciferous vegetables that could potentially provide immunity support and improve certain other regulatory health functions. The Company plans to launch GF and SFN based consumer products in the next six months. According to a recent study led by John Hopkins University and published by Nature, both compounds are shown potential effect in inhibiting the infection of SARS-CoV-2, including Delta and Omicron (Source: Ordonez, A.A., Bullen, C.K., Villabona-Rueda, A.F. et al.

Sulforaphane exhibits antiviral activity against pandemic SARS-CoV-2 and seasonal HCoV-OC43 coronaviruses in vitro and in mice. Commun Biol 5, 242 (2022).). BON has achieved cutting-edge technological breakthroughs in developing such products, including developing a proprietary GF separation platform and various GF based health supplement consumer products with long shelf life and building a high-efficiency SFN production line with proprietary technology to reduce gastrointestinal irritation.

In addition, BON also plants the highest concentration cruciferous vegetables farm to improve the large-scale production. The Company plans to introduce the following health supplement products within the next six months via multiple sales channels, including direct sales to pharmacies and enterprise clients, e-commerce platforms and distributors. These products likely include: Immune system booster in soft gel capsules; Digestive health booster in soft gel capsules; Weight loss management products; Sleep aid products for mid-aged and elderly.